Onco Actu du 24 mai 2018

	1.4 Biologie - Technos
Single-cell approaches to immune profiling [Nature] This is especially important for diseases such as cancer, in which each tumour has unique features that could engage — or suppress — different immune cells.
	2.5 Etiologie - Gènes
Heredity beyond the gene [Nature] Compellingly, Zimmer delves into his own genome. After having it sequenced at 90% coverage by Illumina in San Diego, California, he got his hands on the raw data, and approached experts such as Dina Zielinski of the New York Genome Center to help him unravel his genes’ secrets.
	2.7 Etiologie - Obésité
Diet, Nutrition, Physical Activity and Cancer: a Global Perspective [World Cancer Research Fund] Our Third Expert Report, Diet, Nutrition, Physical Activity and Cancer: a Global Perspective, assesses the past decade of cancer prevention research and the links between diet, nutrition, physical activity and cancer.
Cut out alcohol and bacon to slash cancer risk, say researchers [The Telegraph] The 10-point plan, issued by the The World Cancer Research Fund (WRCF), follows a review of studies on 51 million people – the most comprehensive analysis yet of the causes of the disease.
Obesity now linked to 12 different cancers [The Guardian] Ten years ago, WCRF identified links between obesity and seven cancers. Today, the evidence shows links to 12, says the report presented at the European Congress on Obesity in Vienna.
	4.12 Biopsies liquides
Freenome Sets Sights On Blood Test To Detect Colon Cancer [Forbes] What makes Freenome different is that instead of looking only for circulating DNA from tumors, as other firms are doing, the company is looking at other chemicals the tumors release into the blood, too. It detects patterns in all these chemicals using artificial intelligence.
	4.2 Dép., diag. & prono. - Génome
p53 and Me [NEJM] On my best days, I’m glad I know about my mutation. A physician’s career is predicated on knowing and telling. But I doubt that knowing would be best for everyone.
	4.9 Dép., diag. & prono. - Sein
The heterogeneity of cancer [Breast Cancer Research and Treatment] In other words, bad breast cancers are bad—from the get go. This phenomenon explains the limited ability of mammography to reduce breast cancer mortality. The lack of value in finding microscopic breast cancers (like DCIS) is one of the least well-recognized findings from the ten randomized trials of mammography.
	5. Traitements
Some Children with Wilms Tumor Can Receive Less Therapy, Study Suggests [NCI] The findings from the trial, led by the Children’s Oncology Group (COG), suggest that nearly half of children whose cancer has spread to their lungs can be spared lung radiation therapy without harming their long-term survival.
How gut microbes are joining the fight against cancer [Nature] Zitvogel is not planning to start clinical trials but she has co-founded the Delaware-based start-up EverImmune, which is developing a microbiome-based pill. It’s still unclear exactly how microbes might interact with immunotherapeutics.
	5.12.4 Immunothérapies - Essais
Merck rains on Roche's parade with double Keytruda win in squamous lung cancer [FiercePharma] And now, “the areas in which Keytruda has shown positive data” in lung cancer represent a potential market opportunity of $6.6 billion in the U.S. alone, Credit Suisse analyst Vamil Divan, M.D., wrote to clients.
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival as First-Line Treatment for Squamous Non-Small Cell Lung Cancer (NSCLC) in Pivotal Phase 3 KEYNOTE-407 Tria [Merck] KEYTRUDA Has Now Demonstrated an Improved Survival Benefit in Advanced NSCLC in Five Phase 3 Trials.
Merck crushes Keynote-407 study in frontline lung cancer, hitting co-primaries and setting up another quick OK [EndPoints] The news follows an unusual series of events for the pharma giant, which put out an early release at the beginning of May that the study had hit a key secondary endpoint, triggering a rush to file for an approval.
Merck's Keytruda succeeds in late-stage lung cancer study [Reuters] Keytruda is being studied as a as a first-line treatment for metastatic squamous non-small cell lung cancer patients. The combination therapy met its main trial goals when compared to patients who were on chemotherapy alone.
	5.2.1 Pharma - Partenariats
Amgen Enters Groundbreaking Collaboration To Improve Symptom Management During Cancer Treatment [Amgen] The program will use these insights to develop and deliver a connected solution for patients to be able to better manage their cancer symptoms. While the project will initially be focused on underserved populations in rural, Appalachian Kentucky, the goal is for it to serve as a model for future symptom management projects across the nation.
	5.2.3 Pharma - économie
Look out, J&J. Sun Pharma's Yonsa nod in prostate cancer puts Zytiga on notice [FiercePharma] J&J's Zytiga sales are somewhat insulated from potential competition because the drug generated about half of its revenue outside of the U.S. last year.
Sun Pharma Announces USFDA Approval of YONSA® (abiraterone acetate) To Treat Metastatic Castration-Resistant Prostate Cancer In Combination With Methylprednisolone [Sun Pharma] YONSA® was shown in clinical studies to be an effective form of abiraterone acetate, and can be taken with or without food, in combination with methylprednisolone.
	5.4 Traitements - Economie
A focus on cost instead of value threatens the future of personalized medicine [STAT] Goldman Sachs, for example, issued a report titled “The Genome Revolution.” It argues that while “genome medicine” offers “tremendous value for patients and society,” curing patients may not be “a sustainable business model.”
NICE Issues Technology Appraisal Guidance for Atezolizumab for Treating Locally Advanced or Metastatic NSCLC After Chemotherapy [ESMO] Atezolizumab is recommended if it is stopped at 2 years of uninterrupted treatment or earlier if the disease progresses.
	5.5.1.1 ASCO (général) - Industriels
AstraZeneca heads to 2018 ASCO Annual Meeting with its diversified oncology portfolio and next-generation pipeline [AstraZeneca] 91 accepted abstracts at ASCO, including Lynparza in prostate cancer and moxetumomab pasudotox in hairy cell leukaemia.
	5.5.8 ASCO (poumon)
My Top 5 ASCO 2018 Abstracts in Stage I-III NSCLC, Small Cell Lung Cancer, & Mesothelioma [Jack West - YouTube] Dr. Jack West reviews his top 5 abstracts in stage I-III non-small cell lung cancer, small cell lung cancer, and mesothelioma at ASCO 2018, explaining why each is poised to change the landscape of patient care in this setting.
	6. Lutte contre les cancers
Scientists are declaring war against a leukemia-causing virus that has infected millions [Science] In response to the letter, a WHO spokesperson pointed out that another virus, hepatitis B, causes more than 400,000 cancers each year worldwide. In contrast, the International Agency for Research on Cancer estimates that only 3000 cancer diagnoses annually are directly linked to HTLV-1.
	6.1 Observation
Lung Cancer Incidence in Women under 50 Surpasses that in Men of the Same Age [ACS] This finding has important implications for public health. It may foreshadow a higher future burden of overall lung cancer among women than among men as younger cohorts age, which further underscores the need to intensify antitobacco measures to decrease smoking among young women.
Lung cancer rates in younger white and Hispanic women surpass those of men [Washington Post] Previous research pointed to shifts in the incidence of lung cancer, with rates creeping up among some groups of women. The new study, published in the New England Journal of Medicine, is the largest and most definitive on the topic and one that incorporates smoking patterns and tumor characteristics in its analysis, according to its authors.
	6.10 Politiques
Framework for the UK-EU Partnership Science, Research and Innovation [GOV.UK] This presentation is part of a series produced by the UK negotiating team for discussion with the EU, in order to inform the development of the future framework. It focuses on the UK’s proposals for continued cooperation on science, research and innovation.
	6.10.1 Politiques (USA)
The American Association for Cancer Research Applauds Passage of the Childhood Cancer STAR Act [AACR] Legislation will help kids with cancer live longer, healthier lives.
	6.5 Médecines alternatives
Death from Cancer Quackery – Black Salve Edition [Science-Based Medicine] An Australian nurse dies of cancer while being treated by a cancer quack with a caustic substance known as black salve. How and why is this allowed to happen?
	6.7 DMP, Big Data & applis
Should Tech Entrepreneurs Aspire to Fix Clinical Trials Or Reinvent Them? [Forbes] If traditional trialists are able to deploy technology to drive more efficient recruiting and conduct of trials, that would be a win for patients. The greater use of adaptive design trials would also seem to represent a win for patients.
Precision medicine paradox: Tech outpacing policy [Healthcare IT News] That burdens hospitals with the responsibility to ensure affordability, access and ethics to avoid making a broken healthcare system even worse.
	6.7.1 IA/bioinformatique
Institut Curie names Intel lead partner to implement high performance computing and artificial intelligence in accelerating genome sequencing and interpretation for oncology [Institut Curie] Institut Curie and Intel initiate a pioneering collaboration to develop, use and implement innovative Bioinformatics tools, pipelines and techniques to improve the use of molecular profiling across both research and clinical oncology settings.
	6.9 Controverses
J&J hit with $21.7 million verdict in another talc asbestos cancer case [Reuters] J&J has vehemently denied that its talc products contain asbestos or cause cancer, citing decades of testing by independent laboratories and scientists. But plaintiffs claim that asbestos and talc, which are closely linked minerals, are intermingled in the mining process, making it impossible to remove the carcinogenic substance.